Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.

What Was Tested

The paper reports a study of Glucagon, published as an observational study.

The researchers aimed to investigate the long-term impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on thyroid function, cardiovascular health, renal outcomes and adverse events in individuals with obesity and without type 2 diabetes (T2D).

Who Took Part

According to the abstract, 729,925 individuals were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

In this observational cohort study, the researchers used propensity score matching to construct comparable cohorts of individuals with obesity and without T2D who were new to GLP-1 RA treatment and those who did not receive glucose-lowering medications.

How the Study Was Run

In total, 3,729,925 individuals with obesity were selected from the TriNetX Global Network, with an index event between 1 January 2016 and 31 March 2024.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents, Cardiovascular Diseases, Propensity Score, Cohort Studies and Glucagon-Like Peptide-1 Receptor Agonists.

The authors tagged it with the keywords adverse effects, glucagon‐like peptide‐1 receptor agonists, obesity management and thyroid dysfunction.

What This Means in Plain Language

This is an observational study of Glucagon in 729,925 individuals.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page, all human trials.